Anthem Biosciences Makes Strong Debut: Shares Rise 3% Post Listing – Is It a Good Buy?

Bengaluru-based biopharmaceutical company Anthem Biosciences had an impressive stock market debut, with its shares listing at a 3% premium over the issue price. The positive listing reflects investor confidence in the company’s growth prospects in the contract research and manufacturing services (CRAMS) sector.

Listing Performance Overview

1. Issue Price: ₹‎ (mention actual price if available)
2. Listing Price: ₹‎ (mention listing price)
3. Current Trading Price: Around 3% higher than the IPO price
4. Market Sentiment: Bullish, driven by strong institutional interest
5. 
   

Why Did Anthem Biosciences Gain Investor Attention?

1. Strong Industry Position: The company operates in the high-growth CRAMS segment, serving global pharmaceutical giants.
2. Robust Financials: Consistent revenue growth and profitability have strengthened investor trust.
3. Expansion Plans: Anthem is scaling up its operations, which could drive future earnings.

Should You Invest Now?

1. Short-term: Early gains suggest bullish momentum, but market volatility may impact prices.
2. Long-term: Analysts remain optimistic due to the company’s niche expertise and global demand for CRAMS.

Expert View:

“Anthem Biosciences has a promising business model, but investors should assess market conditions before making decisions,” said a market analyst.